Cardinal Health, Inc. is a prominent healthcare services and products company with a market cap of $37.4 billion, serving over 100,000 locations worldwide, including hospitals and pharmacies. Its shares have surged 53.9% over the past 52 weeks and are up 29.7% in 2025, outperforming major indices. The company’s earnings are expected to grow by 8.6% year-over-year.

The company recently expanded its Equity Rx program to support individuals who cannot afford prescription medications, with a total investment of $5 million. Analysts predict Cardinal’s earnings to reach $8.18 per share for the year ending in June 2025. With a consensus rating of “Strong Buy” from 14 analysts, the stock has seen increased bullish sentiment in recent months.

Morgan Stanley raised Cardinal Health’s price target to $190, maintaining an “Overweight” rating, indicating confidence in the company’s growth. The mean price target of $180.33 suggests a 16.3% premium, with a Street-high target of $197 indicating a 28.4% upside potential. The company continues to show strong performance and growth prospects.

Read more at Yahoo Finance: Do Wall Street Analysts Like Cardinal Health Stock?